Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: VERSATOPE THERAPEUTICS INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2019-09-04 to 2024-09-08
Current total value of award: $9102819
Description: TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.